Nintedanib in Kenya

Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF) and other progressive interstitial lung diseases (ILDs). It slows disease progression by inhibiting pathways involved in lung scarring (fibrosis). Available as 100mg and 150mg soft gelatin capsules in Kenya, it requires prescription and specialist monitoring due to significant risks.

Composition

• Active Ingredient: Nintedanib esilate (equivalent to nintedanib 100mg or 150mg).
• Form: Soft gelatin capsules (opaque, yellow for 100mg; brown for 150mg).
• Inactive Ingredients: Gelatin, glycerol, titanium dioxide, red iron oxide, lecithin.

Side Effects

Common

• Gastrointestinal: Diarrhea (most frequent; 60–70% of patients), nausea, vomiting, abdominal pain.
• Liver Enzyme Elevation: Elevated ALT/AST (monitor closely).
• Fatigue, Weight Loss: Due to reduced appetite.

Serious Risks

• Hepatotoxicity: Severe liver injury (discontinue if ALT/AST >5x ULN).
• Gastrointestinal Perforation: Rare but life-threatening (risk in diverticulitis history).
• Bleeding: Increased risk due to anti-angiogenic effects (avoid with anticoagulants).
• Cardiovascular: Arterial thromboembolic events (e.g., heart attack, stroke).
• Teratogenicity: Contraindicated in pregnancy (causes fetal harm).

How to Use

• Dosage:
  • Standard: 150mg twice daily (12 hours apart).
  • Dose Adjustment: Reduce to 100mg twice daily if intolerable (e.g., severe diarrhea).
• Administration:
  • Take with food to reduce GI side effects.
  • Swallow capsules whole; do not chew/open.
• Monitoring:
  • Liver Function: ALT/AST at baseline, then every 4 weeks.
  • Renal Function: Serum creatinine every 3 months.
  • Diarrhea Management: Loperamide, hydration, dose reduction if persistent.
• Precautions:
  • Avoid if: Moderate-severe hepatic impairment, pregnancy, bleeding disorders.
  • Drug Interactions:
    • CYP3A4 Inhibitors (e.g., ketoconazole): Increase nintedanib levels (avoid).
    • Anticoagulants (e.g., warfarin): Increased bleeding risk (avoid).

Frequently Asked Questions

1. Is Nintedanib available over-the-counter in Kenya?
   No – prescription-only by pulmonologists or ILD specialists.

2. How much does it cost?
   ~KES 15,000–25,000 per 30-capsule pack (monthly cost: KES 90,000–150,000).

3. Does NHIF cover it?
   No – not covered due to high cost; limited access in public hospitals.

4. Can it be used for conditions other than IPF?
   Yes – approved for progressive fibrosing ILDs (e.g., rheumatoid arthritis-associated ILD).

5. What if diarrhea is severe?
   Use loperamide, hydrate, and reduce dose to 100mg twice daily.

6. Are there Kenyan alternatives?
   Pirfenidone (another anti-fibrotic) is available but similarly costly.

7. Is it safe during pregnancy?
   No – women of childbearing age must use contraception.

8. How long does one pack last?
   15 days (150mg twice daily).

Conclusion

Nintedanib is a disease-modifying therapy for IPF and progressive ILDs in Kenya, offering significant survival benefits but limited by extreme cost (KES 90,000–150,000/month) and lack of NHIF coverage. Its use is restricted to major private hospitals and specialized centers due to the need for rigorous monitoring (liver function, diarrhea management). While it slows lung function decline, side effects like diarrhea and hepatotoxicity require proactive management. In Kenya’s resource-constrained setting, access remains a critical barrier, forcing many patients to rely on supportive care alone. For those who can afford it, nintedanib represents a lifeline, but affordability and specialist availability remain unmet needs. Always prioritize multidisciplinary care (pulmonologist, dietitian) to optimize outcomes and manage adverse effects.